Lutter K, Verlohren H J, Lohmann D
Z Gesamte Inn Med. 1978 Feb 15;33(4):113-6.
In the therapy of diabetes mellitus the avoidance of the late cardiovascular complications is at present the largest problem. By the American UGDP-study the attention was paid to an increased death rate of cardiovascular diseases induced possibly by sulfonyl ureas. Since it is ascertained that the disturbance of the fat metabolism which at the same time is frequently present also in diabetes mellitus significantly disturbs the risk for cardiovascular diseases the problem was pursued, to what extent the parameters of the fat metabolism are unfavourably influenced by a therapy with sulfonyl ureas. The result of the investigations was that by an additional intake of 5 mg glibenclamide a day in the usual dietetotherapy with clear improvement of the carbohydrate metabolism there appear no changes in the level of the triglycerides, the cholesterol or the beta-lipoproteids in the serum. By means of this a clear effect of the sulfonyl-ureas on the fat metabolism could be proved.
在糖尿病治疗中，目前最大的问题是避免晚期心血管并发症。美国UGDP研究关注到，磺脲类药物可能导致心血管疾病死亡率增加。由于已确定脂肪代谢紊乱（这在糖尿病中也经常出现）会显著增加心血管疾病风险，因此研究了磺脲类药物治疗在多大程度上会对脂肪代谢参数产生不利影响。研究结果表明，在常规饮食疗法基础上，每天额外摄入5毫克格列本脲，碳水化合物代谢明显改善，但血清中甘油三酯、胆固醇或β-脂蛋白水平无变化。由此可以证明磺脲类药物对脂肪代谢有明显作用。
